To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Parkinson’s podcast: ‘New Neurons for Old’ – interview with Dr Roger Barker
The controversial history of foetal tissue and stem cell therapies
14 hours ago
Study uses Microsoft Xbox sensors to monitor Parkinson’s symptoms
A study by researchers at the University of Miami, US, is using video game technology to help doctors gain a better understanding of Parkinson’s. As part of the research, study participants take part in a 12-week resistance and power training programme. Researchers then use a sensing device – originally designed by Microsoft for the use of Xbox video games – to track the balance and walking patterns of participants, as well as any changes in their symptoms. Researchers believe the results of the study will improve doctors’ understanding of how Parkinson’s medications affect motor function. Joseph Signorile, professor of kinesiology and sport sciences at the University of Miami, said: “In the future this could be in the patient’s home and the physician can monitor their progress. Imagine what this means for someone who lives in a suburban or rural area.”
Monkey study could lead to new Parkinson’s therapies
Scientists at the Texas Biomedical Research Institute, US, are using marmosets – a small monkey species that can mimic the motor and non-motor symptoms of Parkinson’s – to better understand brain changes caused by the condition. The study – published in science journal ‘PLOS ONE’ – induced the monkeys with Parkinson’s motor symptoms such as tremors and used devices similar to Fitbits to monitor their activities. Researchers hope that further analysis will lead to new therapies for people living with the condition. Marcel Daadi, associate scientist at the Texas Biomedical Research Institute and lead author of the study, said: “There are some complex aspects of this disease you simply cannot investigate using rodents in a way that is relevant to human patients. “Nonhuman primates are critical in [this] aspect because we can see these symptoms clearly whether it is the dyskinesia (abnormality or impairment of voluntary movements), or the sleep…
Researchers discover brain network linked to chronic pain in Parkinson’s
Researchers at a French university claim to have discovered the brain network linked to pain in Parkinson’s – called the subthalamic nucleus. People with Parkinson’s who have been treated with deep brain stimulation in this part of the brain have reported reduced symptoms of pain. In a study – published in the science journal eLife – the researchers used electrical signals to stimulate the subthalamic nucleus of rats. They found that healthy rats showed signs of discomfort faster than rats with a damaged subthalamic nucleus. The results also identified the brain pathway through which pain signals travel. Veronique Coizet, senior author of the study, said: “Further experiments are now needed to fully characterise the effects (of) deep brain stimulation on this brain region in our experimental models, with a view to finding ways to optimise it as a treatment for pain caused by Parkinson’s and other neurological diseases.” The researchers…